Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses
 of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
Inclusion Criteria:

 -  History of LUTS for ≥6 months secondary to BPH

 -  Total IPSS (International Prostate Symptom Score) ≥ 13 at Screening

 Exclusion Criteria:

 -